Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis

Fadi N Joudi; Brian J Smith; Michael A O'Donnell; Badrinath R Konety

doi:10.1016/S0090-4295(03)00765-9

Back

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis

Journal article

Peer reviewed

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis

Fadi N Joudi, Brian J Smith, Michael A O'Donnell and Badrinath R Konety

Urology (Ridgewood, N.J.), Vol.62(6), pp.1083-1088

12/2003

DOI: 10.1016/S0090-4295(03)00765-9

PMID: 14665360

View Online

Abstract

To assess the practice preferences among urologists treating superficial bladder cancer in the United States. We surveyed 226 urologists using a specially designed survey instrument. The type of practice, number of urologists in group practice, annual volume of patients with bladder cancer, and those treated with intravesical therapy were assessed. We also obtained information on the American Urological Association section and year of graduation from urology residency training. Of the 226 contacted urologists, 105 (46%) returned a completed survey instrument. Seventeen percent were practicing in academic institutions and 63% were in independent community practice. Forty-five percent had graduated from urology training in or before 1985. Thirty-six percent were in small and 37% were in moderate-size groups. Thirty-five percent were treating a moderate number of patients with bladder cancer, and 44% were treating a large number of patients annually. Thirty-two percent had a moderate number and 40% had a large number of patients receiving intravesical therapy annually. Immunotherapy was preferred in patients at high risk of recurrence. Intravesical chemotherapy was preferred by many for immunotherapy failure. The type of practice and year of graduation were the factors most frequently affecting treatment choice. Practice preferences for the management of superficial bladder cancer are in general agreement with the American Urological Association Bladder Cancer Guidelines Panel recommendations. However, 81% of surveyed urologists were still reluctant to refer patients with high-grade Ta-T1 disease with failure after intravesical immunotherapy twice for more aggressive therapy such as cystectomy or radiotherapy.

United States - epidemiology

Urology - statistics & numerical data

Carcinoma, Transitional Cell - epidemiology

Cystectomy - statistics & numerical data

Humans

Middle Aged

Male

Antineoplastic Agents - therapeutic use

Carcinoma, Transitional Cell - therapy

Data Collection

Professional Practice - statistics & numerical data

Antineoplastic Agents - administration & dosage

Practice Patterns, Physicians' - statistics & numerical data

Urinary Bladder Neoplasms - pathology

Adult

Female

Urinary Bladder Neoplasms - epidemiology

Drug Utilization - statistics & numerical data

Interferon-alpha - therapeutic use

Urology - methods

Radiotherapy - statistics & numerical data

Interferon-alpha - administration & dosage

Immunotherapy - statistics & numerical data

Carcinoma, Transitional Cell - pathology

Urinary Bladder Neoplasms - therapy

Administration, Intravesical

BCG Vaccine - therapeutic use

BCG Vaccine - administration & dosage

Details

Title: Subtitle: Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis
Creators: Fadi N Joudi - Department of Urology, University of Iowa, Iowa City 52242-1089, USA
Brian J Smith
Michael A O'Donnell
Badrinath R Konety
Resource Type: Journal article
Publication Details: Urology (Ridgewood, N.J.), Vol.62(6), pp.1083-1088
Publisher: United States
DOI: 10.1016/S0090-4295(03)00765-9
PMID: 14665360
ISSN: 0090-4295
eISSN: 1527-9995
Language: English
Date published: 12/2003
Academic Unit: Biostatistics; Urology; Holden Comprehensive Cancer Center
Record Identifier: 9983997343602771

Metrics

20 Record Views

39 Times Cited - Web of Science

See more details